TARGET Study Demonstrates Sustained Performance and Favorable Safety Profile of the Cardiovalve TR System in High-Risk Patients with Severe Tricuspid Regurgitation
Late-breaking 6-month full cohort data presented at PCR London Valves 2026 shows durable tricuspid regurgitation reduction up to 3 years, positive right heart remodeling and quality-of-life improvements, as the company advances its CE Mark application. LONDON, Nov. 22, 2026 /PRNewswire/...
Extrait seulement — cet éditeur protège son texte. Lisez le communiqué complet à la source.
Forfait Gratuit · Plus 29 $ CA ou Pro 99 $ CA/mois


